Global, regional, and national burden of myocarditis and cardiomyopathy, 1990-2017

Background: To estimate the burden of myocarditis (MC) and cardiomyopathy for 195 countries and territories from 1990 to 2017. Methods: We collected detailed information on MC and cardiomyopathy between 1990 and 2017 from the Global Burden of Disease study (GBD) 2017. Cardiomyopathy was divided into two types in GBD 2017, including alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC). All estimates were presented as counts, age-standardised rates per 100 000 people and percentage change, with 95% uncertainty intervals (UIs). Results: Worldwide, there were 1.80 million (95% UI 1.64 to 1.98) cases of MC, 1.62 million (95% UI 1.37 to 1.90) cases of AC and 4.21 million (95% UI 3.63 to 4.87) cases of OC, contributing to 46 486 (95% UI 39 709 to 51 824), 88 890 (95% UI 80 935 to 96 290) and 233 159 (95% UI 213 677 to 248 289) deaths in 2017, respectively. At the national level, the age-standardised prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; and the age-standardised death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC. Between 1990 and 2017, despite the decreases in age-standardised rates, the global numbers of prevalent cases and deaths have significantly increased for all the diseases. Females had greater decreases in age-standardised prevalence and death rates than males for all the diseases. Conclusions: MC, AC and OC remain important global public health problems, and there are significant geographic variations in the burden for all these diseases. More effective and geo-specific strategies are necessary to counteract and mitigate the future burden of these diseases.

Download Full-text

Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990–2017

Frontiers in Cardiovascular Medicine ◽

10.3389/fcvm.2021.610989 ◽

2021 ◽

Vol 8 ◽

Author(s):

Haijiang Dai ◽

Dor Lotan ◽

Arsalan Abu Much ◽

Arwa Younis ◽

Yao Lu ◽

...

Keyword(s):

National Level ◽

Treatment Programs ◽

Years Of Life Lost ◽

Global Public Health ◽

Geographic Variations ◽

Systematic Assessment ◽

National Burden ◽

Potential Risk Factors ◽

System Resource ◽

Disease Study

Objective: To estimate the burden of myocarditis (MC), alcoholic cardiomyopathy (AC), and other cardiomyopathy (OC) for 195 countries and territories from 1990 to 2017.Methods: We collected detailed information on MC, AC, and OC between 1990 and 2017 from the Global Burden of Disease study 2017, which was designed to provide a systematic assessment of health loss due to diseases and injuries in 21 regions, covering 195 countries and territories. Estimates of MC, AC, and OC burden were produced using a standard Cause of Death Ensemble model and a Bayesian mixed-effects meta-regression tool, and included prevalence, deaths, years lived with disability (YLDs), and years of life lost (YLLs). All estimates were presented as counts, age-standardized rates per 100,000 people and percentage change, with 95% uncertainty intervals (UIs).Results: Worldwide, there were 1.80 million (95% UI 1.64–1.98) cases of MC, 1.62 million (95% UI 1.37–1.90) cases of AC and 4.21 million (95% UI 3.63–4.87) cases of OC, contributing to 46,486 (95% UI 39,709–51,824), 88,890 (95% UI 80,935–96,290), and 233,159 (95% UI 213,677–248,289) deaths in 2017, respectively. Furthermore, globally, there were 131,376 (95% UI 90,113–183,001) YLDs and 1.26 million (95% UI 1.10–1.42) YLLs attributable to MC, 139,087 (95% UI 95,134–196,130) YLDs and 2.84 million (95% UI 2.60–3.07) YLLs attributable to AC, and 353,325 (95% UI 237,907–493,908) YLDs and 5.51 million (95% UI 4.95–5.99) YLLs attributable to OC in 2017. At the national level, the age-standardized prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; the age-standardized death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC; the age-standardized YLD rates varied by 12.4 times for MC, 223.7 times for AC, and 34.1 times for OC; and the age-standardized YLL rates varied by 38.4 times for MC, 684.8 times for AC, and 36.2 times for OC. Between 1990 and 2017, despite the decreases in age-standardized rates, the global numbers of prevalent cases, deaths, YLDs, and YLLs have increased for all the diseases.Conclusion: Accurate assessment of the burden of MC, AC, and OC is essential for formulating effective preventative prevention and treatment programs and optimizing health system resource allocation. Our results suggest that MC, AC, and OC remain important global public health problems with increasing numbers of prevalent cases, deaths, YLDs, and YLLs over the past decades, and there are significant geographic variations in the burden of these diseases. Further research is warranted to expand our knowledge of potential risk factors and to improve the prevention, early detection and treatment of these diseases.

Download Full-text

Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017

Rheumatology ◽

10.1093/rheumatology/keaa315 ◽

2020 ◽

Author(s):

Saeid Safiri ◽

Ali Asghar Kolahi ◽

Marita Cross ◽

Kristin Carson-Chahhoud ◽

Amir Almasi-Hashiani ◽

...

Keyword(s):

Burden Of Disease ◽

National Level ◽

Point Prevalence ◽

Global Burden Of Disease ◽

Global Burden ◽

Disability Adjusted Life ◽

Life Years ◽

Prevalence Estimates ◽

National Burden ◽

Disease Study

Abstract Objectives To describe the level and trends of point prevalence, deaths and disability-adjusted life years (DALYs) for other musculoskeletal (MSK) disorders, i.e. those not covered by specific estimates generated for RA, OA, low back pain, neck pain and gout, from 1990 to 2017 by age, sex and sociodemographic index. Methods Publicly available modelled estimates from the Global Burden of Disease (GBD) 2017 study were extracted and reported as counts and age-standardized rates per 100 000 population for 195 countries and territories between 1990 and 2017. Results Globally, the age-standardized point prevalence estimates and deaths rates of other MSK disorders in 2017 were 4151.1 and 1.0 per 100 000. This was an increase of 3.4% and 7.2%, respectively. The age-standardized DALY rate in 2017 was 380.2, an increase of 3.4%. The point prevalence estimate was higher among females and increased with age. This peaked in the 65–69 year age group for both females and males in 2017, followed by a decreasing trend for both sexes. At the national level, the highest age-standardized point prevalence estimates in 2017 were seen in Bangladesh, India and Nepal. The largest increases in age-standardized point prevalence estimates were observed in Romania, Croatia and Armenia. Conclusion The burden of other MSK disorders is proven to be substantial and increasing worldwide, with a notable intercountry variation. Data pertaining to specific diseases within this overarching category are required for future GBD MSK estimates. This would enable policymakers to better allocate resources and provide interventions appropriately.

Download Full-text